UK Markets closed

ReNeuron Group plc (RENE.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
28.00+0.25 (+0.90%)
At close: 05:06PM BST
Sign in to post a message.
  • g
    georgejjl
    ReNeuron Group plc Announces Positive Preliminary Data in U.S. Retinitis Pigmentosa Trial

    hRPC Cell Therapy Demonstrates Significant Restoration of Vision in First Cohort of Phase 2 Study in Retinitis Pigmentosa

    LONDON, Feb. 20, 2019 /PRNewswire/ -- ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announced positive preliminary results in the Company's ongoing Phase 1/2 clinical trial of its human retinal progenitor cells (hRPC) cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).

    All three subjects in the first cohort of the Phase 2 part of the trial have demonstrated a significant improvement in vision at follow-up compared with their pre-treatment baseline and compared with their untreated control eye. At most recent follow-up, subjects showed average improvement equivalent to reading an additional three lines of five letters on the ETDRS eye chart, the standardised eye chart used to measure visual acuity in clinical trials.

    The Phase 2 part of the Phase 1/2 trial, which uses a cryopreserved, commercially ready hRPC formulation, enrolls subjects with some retinal functionality, in contrast to the very poor vision and lack of potential for improvement of the subjects in the trial's Phase 1 component.

    In the latest observations of the first Phase 2 cohort, at two months follow-up for one subject, and at 18 days for the other two, all three subjects have reported improved vision, with standardised eye chart testing showing objective improvement in visual acuity compared with their pre-treatment baseline vision and compared with the patients' untreated control eye.

    Jason Comander M.D., Ph.D., Associate Director, Inherited Retinal Disorders Service, Massachusetts Eye and Ear, and Assistant Professor, Harvard Medical School, and the trial's principal investigator, said, "It is exciting to move into a population of patients whose remaining vision and retinal architecture support the possibility of visual improvement and I am very much looking forward to obtaining additional results from this patient cohort and the next."

    Pravin Dugel M.D., Managing Partner, Retinal Consultants of Arizona, Phoenix, Arizona, and Clinical Professor, Roski Eye Institute, USC Keck School of Medicine, Los Angeles, California and the first Phase 2 cohort's other investigator, said: "When I heard about the rapidity and magnitude of the visual gain in the first patient that Jason treated in this cohort, I was hopeful, but sceptical. Now that I saw this repeated in my first two patients, I am very excited indeed."

    The Company notes that these data are early and it will continue to generate further data, including regular ongoing monitoring of the three treated subjects, to assess durability of effect and efficacy over a longer period of time and in a larger number of patients.

    Summary of the preliminary efficacy data from the three Phase 2 subjects treated to date (visual acuity measured using the standardized ETDRS chart)

    For the first subject in the cohort, visual acuity improved in the treated eye from nine letters at baseline to 29 letters at two months follow-up; for the second subject, visual acuity improved from nine letters at baseline to 24 letters at 18 days follow-up; for the third subject, visual acuity improved from 32 letters at baseline to 46 letters at 18 days follow-up. The mean change from baseline in visual acuity for these first three subjects thus far is +16 letters in the study eye, compared with a mean change from baseline of -1 letter in the untreated control eye. All three subjects have noted a subjective improvement in vision in their treated eye. The untreated control eyes did not show significant improvement (mean change from baseline -1 letter, range -5 to + 5 letters).

    The Phase 1/2 study, which is being conducted at two clinical sites in the U.S. – Massachusetts Eye and Ear in Boston and Retinal Research Institute in Phoenix, Arizona – is an open-label study to evaluate the safety, tolerability and preliminary efficacy of the hRPC stem cell therapy candidate in patients with advanced RP. RP is a group of hereditary diseases of the eye that lead to progressive loss of sight due to cells in the retina becoming damaged and eventually dying.

    Dosing in the Phase 1 part of the study was completed last year in 12 subjects with extensive retinal damage and very limited remaining vision to establish the safety of the treatment. The safety and visual stability data from this part of the study resulted in the Data Safety Monitoring Board (DSMB) approving the transition to a commercially ready hRPC drug product formulation to be administered to patients with less retinal damage and consequently better visual potential.

    Dosing of the second cohort of three Phase 2 subjects is expected to commence in March 2019 following DSMB review of the clinical data from the first Phase 2 cohort.
    Home - ReNeuron
    www.reneuron.com.
  • g
    georgejjl
    ReNeuron to Present at the H.C. Wainwright Global Life Sciences Conference
    April 5, 2019
    ReNeuron Group plc (RENE.L), a UK-based global leader in the development of cell-based therapeutics, today announced that Olav Hellebø, the Company's Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 9, 2019 at 3:30 p.m. BST at the Grosvenor House in London.

    A live and archived webcast of the H.C. Wainwright presentation will be available on the Webcasts & Presentations page of the company's website at www.reneuron.com.

    About ReNeuron
    ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.

    https://finance.yahoo.com/news/reneuron-present-h-c-wainwright-110000085.html

    Good luck and GOD bless,
    Home - ReNeuron
    www.reneuron.com.
  • g
    georgejjl
    ARVO 2019 Highlight: RP Patients in ReNeuron’s Cell Therapy Trial Show Further Vision Improvements
    The latest ReNeuron results were presented at the sixth annual Retinal Cell and Gene Therapy Innovation Summit held on April 26 in Vancouver, Canada.

    ReNeuron, a developer of cell-based therapies, has reported that the first three patients with retinitis pigmentosa (RP) in the Phase 2a cohort of its Phase 1/2 clinical trial have demonstrated sustained and further vision improvements since receiving the company’s human retinal progenitor cells (hRPC).

    The hRPC are stem cells that have almost matured into photoreceptors, the retinal cells that make vision possible. The goal of the emerging treatment is to restore vision in people with RP and related conditions.

    “The results for the ReNeuron trial continue to be promising. The improvements in visual acuity, which reflects the ability to perceive more detail and read smaller letters, are especially encouraging,” says Brian Mansfield, PhD, executive vice president of research and interim chief scientific officer at the Foundation Fighting Blindness. “We look forward to additional reports from the clinical study as it moves forward with more participants.”

    The first subject in the Phase 2a cohort showed a 21-letter improvement (4 lines on an eye chart) in visual acuity at 120 days after receiving the treatment. Earlier, that subject had a 20-letter improvement at 60 days.

    The second subject in the Phase 2a cohort showed a 25-letter improvement (5 lines on an eye chart) at 60 days after receiving the treatment. Earlier, that subject had a 15-letter improvement at 18 days.

    The third subject in the Phase 2a cohort showed a 23-letter improvement (more than 4 lines on an eye chart) at 60 days after receiving the treatment. Earlier, that subject had a 14-letter improvement at 18 days.

    Patients in the Phase 2a group had better vision at trial enrollment than those in the Phase 1 group. Those in Phase 1, which primarily focused on treatment safety, did not experience vision improvements.

    The Foundation Fighting Blindness funded Michael Young, PhD, Massachusetts Eye and Ear, for pre-clinical and translational studies for the hRPC that helped make the ReNeuron trial possible.

    The latest ReNeuron results were presented by Jason Comander, MD, PhD, a lead investigator for the trial at Massachusetts Eye and Ear, at the sixth annual Retinal Cell and Gene Therapy Innovation Summit on April 26. The summit, hosted by the Foundation Fighting Blindness and Casey Eye Institute, Oregon Health & Science University, preceded the 2019 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) taking place in Vancouver, Canada, on April 28 – May 2.

    https://www.fightingblindness.org/research/arvo-2019-highlight-rp-patients-in-reneuron-s-cell-therapy-trial-show-further-vision-improvements-14

    Good luck and GOD bless,
    The latest ReNeuron results were presented at the sixth annual Retinal Cell and Gene Therapy Innovation Summit held on April 26 in Vancouver, Canada.
    The latest ReNeuron results were presented at the sixth annual Retinal Cell and Gene Therapy Innovation Summit held on April 26 in Vancouver, Canada.
    www.fightingblindness.org
  • g
    georgejjl
    NEWS within 2 weeks from TODAY June 27, 2019

    Quote:
    ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of
    cell-based therapeutics, will webcast the analyst briefing on the day of its
    preliminary results, Thursday 11 July 2019.
    To listen to the webcast live, please log on to the following web address
    approximately 5 minutes before 10.00am BST on the day of results:
    https://webcasting.buchanan.uk.com/broadcast/5d011332221579216107d918
    A recording of the webcast will later be made available at ReNeuron’s website,
    www.reneuron.com.
    The analyst briefing will be held at 10.00am BST on 11 July 2019 at the offices of
    Buchanan, 107 Cheapside, London EC2V 6DN.
    For more information, please contact Buchanan on reneuron@buchanan.uk.com

    http://4965zs3ha2l125fk78zkozo3.wpengine.netdna-cdn.com/wp-content/uploads/ReNeuron-Results-webcast-RNS-FINAL.pdf

    Good luck and GOD bless,
  • g
    georgejjl
    ReNeuron : Appointments to Scientific Advisory Board
    share with twitter share with LinkedIn share with facebook share via e-mail
    0
    08/22/2019 | 08:44am EDT
    ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces the appointment of Professor Robert MacLaren, Dr Sally Temple and Dr Jose-Alain Sahel to its Scientific Advisory Board.

    Professor Robert MacLaren is Professor of Ophthalmology at the University of Oxford, where he directs research into developing new clinical treatments for blindness, using stem cells, gene therapy and electronic retinal implants. In 2016 he performed the world's first operation inside the human eye using a remotely controlled robot. Together with the University of Oxford, in 2014 he co-founded Nightstar Therapeutics, a biotechnology company originally based at the Wellcome Trust in London, to develop gene therapy treatments for patients with retinal diseases. Nightstar was acquired for $800 million by Nasdaq-listed Biogen, Inc. in June 2019.

    Dr Sally Temple is the Scientific Director of the Neural Stem Cell Institute in New York. She leads a team of 30 researchers focused on using neural stem cells to develop therapies for eye, brain, and spinal cord disorders. In 1989, she discovered that the embryonic mammalian brain contained a rare stem cell that could be activated to proliferate in vitro and produce both neurons and glia. Since then, her team has continued to make pioneering contributions to the field of stem cell research. Their research on the characterisation of neural stem and progenitors brings closer the prospect of effective clinical treatments for central nervous system damage in which tissue is lost, for example, due to neurodegenerative diseases or trauma.

    Dr Jose-Alain Sahel is the chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine, of the UPMC Eye Center, and the Eye and Ear Foundation Endowed Chair of Ophthalmology. He founded and still heads the Institut de la Vision (Sorbonne Universite-Inserm-CNRS) in Paris, one of the largest Vision Research Centres worldwide. Dr Sahel is known worldwide for his expertise in vision restoration techniques. He has led pioneering efforts in neuroprotection, prosthetic and optogenetic vision restoration, a technique in which cells in the retina are genetically modified to express light sensitive proteins. Dr Sahel founded Fovea Pharmaceuticals, which later became the Ophthalmology Division of Sanofi Aventis. He is also a scientific co-founder of GenSight Biologics, Pixium Vision and Sparing Vision. He is a member of the French and German National Academies of Science.

    ReNeuron'sScientific Advisory Board is composed of leading academics and industry executives with a world-class breadth of expertise across the Company's areas of operation. Its role is to advise the Company on scientific matters relating to its research and clinical development strategy. This includes the future direction of cell therapy, links to academic, regulatory and industrial organisations and relationships with peer companies and government bodies on a global basis.

    Olav Hellebo, Chief Executive Officer of ReNeuron, commented: 'We are delighted to welcome these renowned experts to our Scientific Advisory Board. They will provide invaluable insight and counsel across ReNeuron's therapeutic programmes as we progress our pioneering therapies towards commercialisation.'

    Contact:

    Tel: +44 (0)20 3819 8400

    About ReNeuron

    ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.

    https://www.marketscreener.com/RENEURON-GROUP-PLC-4005458/news/ReNeuron-Appointments-to-Scientific-Advisory-Board-29101004/

    Good luck and GOD bless,
    ReNeuron Group plc , a UK-based global leader in the development of cell-based therapeutics, today announces the appointment of Professor Robert MacLaren, Dr Sally Temple and Dr Jose-Alain Sahel to... | August 22, 2019
    ReNeuron Group plc , a UK-based global leader in the development of cell-based therapeutics, today announces the appointment of Professor Robert MacLaren, Dr Sally Temple and Dr Jose-Alain Sahel to... | August 22, 2019
    www.marketscreener.com
  • g
    georgejjl
    ReNeuron wins Breakthrough of the Year Award
    ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based
    therapeutics, is delighted to announce that it has won the ‘Breakthrough of the Year’ award at
    last night’s 2019 European Mediscience Awards in London.
    This award underlines the strong clinical development and commercial progress ReNeuron has
    made over the past year. This includes positive data from the ongoing Phase 1/2a clinical trial
    in Retinitis Pigmentosa and the signing of an exclusive licence agreement with Shanghai Fosun
    Pharmaceutical Industrial Development Co., Ltd. for the development, manufacture and
    commercialisation of ReNeuron’s CTX and hRPC cell therapy programmes in the People’s
    Republic of China.
    Olav Hellebø, Chief Executive Officer of ReNeuron, commented:
    “We are delighted to have been awarded the Breakthrough of the Year award at the 2019
    European Mediscience Awards. We are greatly encouraged by the progress we have made with
    our cell therapy clinical development programmes for retinitis pigmentosa and stroke disability
    over the past year and look forward to continuing to advance our clinical and business
    development activities in the months ahead.”
    The European Mediscience Awards is one of the largest annual gathering of private and publicly
    quoted healthcare, biotech and life sciences companies in Europe. It celebrates the best in the
    sector and highlights the achievements of individuals and companies operating within it.
    ENDS
    Contacts:
    ReNeuron +44 (0) 20 3819 8400
    Olav Hellebø, Chief Executive Officer
    Michael Hunt, Chief Financial Officer
    Buchanan (UK Media/Investor Relations) +44 (0) 20 7466 5000
    Mark Court, Sophie Wills, Tilly Abraham
    Argot Partners (US Media/Investor Relations) +1 212 600 1902
    Stephanie Marks, Claudia Styslinger
    Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)
    Jonathan Senior, Stewart Wallace, Ben Maddison
    +44 (0) 20 7710 7600
    N+1 Singer (Joint Broker)
    Aubrey Powell, Mark Taylor
    +44 (0) 20 7496 3000
    About ReNeuron
    ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell
    technologies to develop ‘off-the-shelf’ stem cell treatments, without the need for
    immunosuppressive drugs. The Company’s lead clinical-stage candidates are in
    development for the blindness-causing disease, retinitis pigmentosa and for disability
    as a result of stroke. ReNeuron is also advancing its proprietary exosome technology
    platform as a potential delivery system for drugs that would otherwise be unable to
    reach their site of action. ReNeuron’s shares are traded on the London AIM market
    under the symbol RENE.L. Further information on ReNeuron and its products can be
    found at www.reneuron.com.
    Home - ReNeuron
    www.reneuron.com.
  • g
    georgejjl
    Foundation Fighting Blindness to Host 6th Annual Retinal Cell & Gene Therapy Innovation Summit Before ARVO
    SOURCE Foundation Fighting Blindness

    The Summit, which will bring physicians, scientists, and industry together to collaboratively advance innovation for emerging retinal therapies, will be held Friday, April 26, 2019.

    COLUMBIA, Md., April 23, 2019 /PRNewswire/ -- The Foundation Fighting Blindness, a national nonprofit focused on funding cutting-edge retinal disease research, will co-host the sixth annual Retinal Cell and Gene Therapy Innovation Summit, in partnership with the Casey Eye Institute at Oregon Health & Science University. The Summit – one of the world's most comprehensive reviews (three dozen presenters) of ongoing and planned clinical research for retinal degenerative diseases – will be held in Vancouver, British Columbia, on Friday, April 26, 2019, prior to the 2019 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO).

    At the summit, representatives from biotech and pharma industries will come together with members of the physician and scientist communities to discuss rapidly emerging retinal gene, cell and novel therapies and strategize how to move the emerging options forward. The summit features presentations by leading retinal disease experts on potential gene and stem-cell therapies and how best to deliver them to patients.

    "The purpose of the Summit is to create visibility for the many projects based on gene or cell therapy approaches that are in or entering the clinic," said Brian Mansfield, PhD, executive vice president, interim chief scientific officer. "These approaches, many of which were initiated or supported with funding from the Foundation, hold strong promise for the treatment of diseases of the retina, such as age-related macular degeneration and inherited conditions such as retinitis pigmentosa and Stargardt disease. This progress is occurring due to the expertise and collaboration of companies, clinicians, and scientists, many of whom will attend the summit."

    Summit registration is open to academic, physician, biotech and pharmaceutical representatives, as well as industry media interested in learning more about the collaborative advancements featured at the Summit. For additional information, please visit https://www.regonline.com/InnovationSummitVancouver.

    Presentations of Note
    FRIDAY, APRIL 26

    1:45 PM – 2:00 PM: Subretinal implantation of human retinal progenitor stem cells
    Dr. Jason Comander, Massachusetts Eye and Ear

    Here, Dr. Comander will review early, encouraging vision improvements for the ReNeuron Phase 2 retinal progenitor clinical trial for patients with retinopathy of prematurity.

    http://www.wfmj.com/story/40350440/foundation-fighting-blindness-to-host-6th-annual-retinal-cell-gene-therapy-innovation-summit-before-arvo

    Good luck and GOD bless,
    When: Friday, April 26, 2019. Where: Fairmont Hotel Vancouver, 900 West Georgia Street Vancouver, British Columbia V6C 2W6 Canada. General Meeting Questions: Corrie Simkin-Brocato Ph: 410-423-0579 CSimkin-Brocato@FightBlindness.org Sponsorship
    When: Friday, April 26, 2019. Where: Fairmont Hotel Vancouver, 900 West Georgia Street Vancouver, British Columbia V6C 2W6 Canada. General Meeting Questions: Corrie Simkin-Brocato Ph: 410-423-0579 CSimkin-Brocato@FightBlindness.org Sponsorship
    www.regonline.com
  • g
    georgejjl
    ReNeuron Group Plc (LON:RENE) insider John Edward Berriman acquired 80,000 shares of the company’s stock in a transaction dated Thursday, April 11th. The shares were bought at an average price of GBX 225 ($2.94) per share, for a total transaction of £180,000 ($235,201.88).

    https://www.modernreaders.com/news/2019/04/19/reneuron-group-plc-rene-insider-buys-180000-in-stock.html

    Quote:
    John Edward Berriman BEng, MBA, is Non-Executive Chairman of the Board of ReNeuron Group PLC. He was appointed to the Board in July 2011 and became Chairman in March 2015. He is the Chairman of Autifony Therapeutics Ltd and past Chairman of Heptares Therapeutics Ltd (sold to Sosei in February 2015) and Algeta ASA (sold to Bayer AG in 2014 and previously listed on the Oslo stock exchange). He is also a nonexecutive Director of Cytos AG (listed on the SIX Swiss exchange). Until its sale to Amgen in the spring of 2012 he was a Director of Micromet Inc. (listed on NASDAQ). Previously he was a Director of Abingworth Management, an international healthcare venture capital firm.

    WHAT IS THE SALARY OF JOHN BERRIMAN?
    As the Non-Executive Chairman of the Board of ReNeuron plc, the total compensation of John Berriman at ReNeuron plc is $31,000.

    https://wallmine.com/otc/rnugf/officer/1141952/john-berriman

    A total transaction of £180,000 ($235,201.88) is definitely a significant purchase at the market price.

    Good luck and GOD bless,
    ReNeuron Group Plc (LON:RENE) insider John Edward Berriman acquired 80,000 shares of the company’s stock in a transaction dated Thursday, April 11th. The shares were bought at an average price of GBX 225 ($2.94) per share, for a total transaction of
    ReNeuron Group Plc (LON:RENE) insider John Edward Berriman acquired 80,000 shares of the company’s stock in a transaction dated Thursday, April 11th. The shares were bought at an average price of GBX 225 ($2.94) per share, for a total transaction of
    www.modernreaders.com
  • g
    georgejjl
    hRPC moves to centre stage

    The recent early but striking data on ReNeuron's hRPC product for treating RP has become the focus of investor attention. This is because the data reported so far are good, the study has a placebo-controlled element (with one of the patient’s eyes untreated) and the results for all 12 of the patients in the Phase IIa study are expected to be reported in H219. We have not changed the timelines for the first regulatory approval for the hRPC product, which we had estimated to be in 2023, but the possibility exists that this timeline could accelerate if the data continue to prove compelling. In a similar way, the clinical trial results to date have raised the profile of this programme and, bearing in mind the cash-rich, innovative product-poor status of many big pharmaceutical and biotechnology companies, we would not be surprised to see another licensing transaction for the hRPC product.

    https://www.edisongroup.com/publication/year-end-update-highlights-transaction-potential-2/24196

    Good luck and GOD bless,
    ReNeuron’s year-end update summarised its recent clinical progress in the human retinal progenitor cell (hRPC) programme in retinitis pigmentosa (RP), which has become the focus for investors, and a slight delay to its CTX programme for stroke disabi
    ReNeuron’s year-end update summarised its recent clinical progress in the human retinal progenitor cell (hRPC) programme in retinitis pigmentosa (RP), which has become the focus for investors, and a slight delay to its CTX programme for stroke disabi
    www.edisongroup.com
  • S
    Steven
    Latest reaction 2yrs... I'm trying to find out why we are jumping up recently? I am very long on this, and it has been abysmal up until quite recently. Not sure what's going on....
  • g
    georgejjl
    Scientists on brink of CURING blindness after patient has eyesight RESTORED

    BRITISH scientists are on the brink of curing blindness following the success of a procedure which repairs damaged retina.

    Scientists have successfully improved the vision of three legally blind patients, with one having their eyesight restored. All three patients had retinitis pigmentosa, an inherent disease which slowly constricts vision. The disease currently has no cure but a British firm has reported early success with a procedure which helps to repair the damaged retina.

    Before the procedure, the patients were legally blind and could only read the largest group of letters on a special eye test chart.

    But 18 days after being injected with stem cells, their sight had improved to the point where they could read three letter sizes smaller.

    One patient is no longer classified as legally blind and another said she was able to see the food on her plate for the first time in years.

    Olav Hellebo, chief executive of UK biotech firm ReNeuron, said the women went from being capable of seeing nine letters on the eye test chart to 29.

    People are considered legally blind if they can read less than 36 letters on the 100-letter chart.

    Mr Hellebo said: “She said she could now see the food on her plate, which is really motivating for us to hear.”

    The two men improved their eyesight from nine to 24 and from 31 to 45.

    The treatment for retinitis pigmentosa requires growing billions of progenitor stem cells in a laboratory.

    These have the capability to transform themselves into other types of cells depending on where they are located in the body.

    One million stem cells are injected into the back of the patient’s eyeball.

    Once there, they transform into new light-sensitive cells called rods and cones which replace ones that have been lost prematurely because of genetic flaws.

    Olav Hellebo said the tests on the patients had produced “exciting” results.

    “We are obviously very excited. We have to bear in mind all the caveats – that these are results in only three patients and it is early days – but the reaction from ophthalmologists has been very encouraging,” Mr Hellebo told the Mail on Sunday.

    Development of the technology has been led by experts at ReNeuron in Bridgend, Wales.

    A further nine patients will now have the procedure.

    Retinitis pigmentosa, which affects around 25,000 people in the UK, is caused by about 100 inherited genetic defects.

    The loss of vision can start in childhood, adolescence or adulthood.

    It starts with deteriorating night vision and peripheral vision which then narrows and leaves people with only hazy tunnel vision.

    Total blindness usually follows.

    Tina Houlihan, of the Retina UK charity which supports people with inherited sight loss, said: “These early results are encouraging and will provide hope to those living with retinitis pigmentosa.

    “However, while the trial is at this very early stage, with only a very small number of patients involved, we are cautious in our optimism.”

    https://www.express.co.uk/news/uk/1114039/blindness-cure-eyesight-problems-doctor-retinitis-pigmentosa

    Good luck and GOD bless,
    BRITISH scientists are on the brink of curing blindness following the success of a procedure which repairs damaged retina.
    BRITISH scientists are on the brink of curing blindness following the success of a procedure which repairs damaged retina.
    www.express.co.uk
  • g
    georgejjl
    ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of
    cell-based therapeutics, will webcast the analyst briefing on the day of its
    preliminary results, Thursday 11 July 2019.
    To listen to the webcast live, please log on to the following web address
    approximately 5 minutes before 10.00am BST on the day of results:
    https://webcasting.buchanan.uk.com/broadcast/5d011332221579216107d918
    A recording of the webcast will later be made available at ReNeuron’s website,
    www.reneuron.com.
    The analyst briefing will be held at 10.00am BST on 11 July 2019 at the offices of
    Buchanan, 107 Cheapside, London EC2V 6DN.
    For more information, please contact Buchanan on reneuron@buchanan.uk.com
    or 020 7466 5000.
    ENDS
    ENQUIRIES:
    ReNeuron +44 (0)20 3819 8400
    Olav Hellebø, Chief Executive Officer
    Michael Hunt, Chief Financial Officer
    Buchanan (UK) +44 (0) 20 7466 5000
    Mark Court, Sophie Wills, Tilly Abraham
    Argot Partners (US)
    Stephanie Marks, Claudia Styslinger
    Stifel Nicolaus Europe Limited

    +1 212 600 1902

    +44 (0) 20 7710 7600
    Jonathan Senior, Stewart Wallace, Ben Maddison
    (NOMAD and Joint Broker)
    Nplus1 Singer Advisory LLP +44 (0) 20 7496 3000
    Aubrey Powell, Mark Taylor (Joint Broker)
    About ReNeuron
    ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem
    cell technologies to develop ‘off the shelf’ stem cell treatments, without the need
    for immunosuppressive drugs. The Company’s lead clinical-stage candidates are in
    development for the blindness-causing disease, retinitis pigmentosa, and for
    disability as a result of stroke. ReNeuron is also advancing its proprietary exosome
    technology platform as a potential delivery system for drugs that would otherwise
    be unable to reach their site of action. ReNeuron’s shares are traded on the
    London AIM market under the symbol RENE.L. For further information visit
    www.reneuron.com.
  • g
    georgejjl
    ",,,stem cell researcher Reneuron up 22% due to positive clinical trials for a blindness treatment. That brought year-to-date returns to 520% making it the second largest riser in the FTSE Aim All Share Index this year, just behind 541.7% returns from MX Oil, according to Bloomberg data....:"

    https://portfolio-adviser.com/woodford-backed-stem-cell-company-rallies-520/

    Good luck and GOD bless,
    Prothena also examines way forward for drug put on hold in 2018 #hargreaveslansdown #healthcare #prothena
    Prothena also examines way forward for drug put on hold in 2018 #hargreaveslansdown #healthcare #prothena
    portfolio-adviser.com
  • g
    georgejjl
  • g
    georgejjl
    Just 7 calendar days from NEWS on Thursday July 11, 2019

    Quote:
    ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will webcast the analyst briefing on the day of its preliminary results, Thursday 11 July 2019.

    To listen to the webcast live, please log on to the following web address approximately 5 minutes before 10.00am BST on the day of results:
    https://webcasting.buchanan.uk.com/broadcast/5d011332221579216107d918

    A recording of the webcast will later be made available at ReNeuron’s website, www.reneuron.com.

    The analyst briefing will be held at 10.00am BST on 11 July 2019 at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

    For more information, please contact Buchanan on reneuron@buchanan.uk.com
    or 020 7466 5000.

    http://4965zs3ha2l125fk78zkozo3.wpengine.netdna-cdn.com/wp-content/uploads/ReNeuron-Results-webcast-RNS-FINAL.pdf

    Good luck and GOD bless,
    Sign up - ReNeuron - Prelim Results
    webcasting.buchanan.uk.com
  • g
    georgejjl
    ReNeuron Group Plc (RENE) Insider Buys £180,000 in Stock
    Posted by Anthony Bellafiore on Apr 27th, 2019

    ReNeuron Group logoReNeuron Group Plc (LON:RENE) insider John Edward Berriman bought 80,000 shares of the company’s stock in a transaction dated Thursday, April 11th. The shares were purchased at an average price of GBX 225 ($2.94) per share, with a total value of £180,000 ($235,201.88).

    Shares of RENE opened at GBX 310 ($4.05) on Friday. ReNeuron Group Plc has a one year low of GBX 29.50 ($0.39) and a one year high of GBX 257 ($3.36). The stock has a market capitalization of $98.14 million and a price-to-earnings ratio of -7.33.

    https://www.modernreaders.com/news/2019/04/27/reneuron-group-plc-rene-insider-buys-180000-in-stock.html

    Good luck and GOD bless,
  • g
    georgejjl
    Webcast of Preliminary Results
    ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of
    cell-based therapeutics, will webcast the analyst briefing on the day of its
    preliminary results, Thursday 11 July 2019.
    To listen to the webcast live, please log on to the following web address
    approximately 5 minutes before 10.00am BST on the day of results:
    https://webcasting.buchanan.uk.com/broadcast/5d011332221579216107d918
    A recording of the webcast will later be made available at ReNeuron’s website,
    www.reneuron.com.
    The analyst briefing will be held at 10.00am BST on 11 July 2019 at the offices of
    Buchanan, 107 Cheapside, London EC2V 6DN.
    For more information, please contact Buchanan on reneuron@buchanan.uk.com
    or 020 7466 5000.
    ENDS
    ENQUIRIES:
    ReNeuron +44 (0)20 3819
    Sign up - ReNeuron - Prelim Results
    webcasting.buchanan.uk.com
  • g
    georgejjl
    The Company is aware of the following significant (3% or greater) shareholdings in the Company’s ordinary shares:

    Woodford Investment Management Limited 35.39%
    Arthurian Life Sciences SPV GP Ltd, as GP of The Wales Life Sciences Investment Fund LP 9.48%

    http://www.reneuron.com/investors/major-shareholdings/

    Good luck and GOD bless,
    Major Shareholdings - ReNeuron
    www.reneuron.com
  • g
    georgejjl
    ReNeuron Partners with Fosun Pharma in China
    PR Newswire
    PR NewswireApril 9, 2019, 7:00 AM EDT
    ReNeuron licenses rights to its CTX and hRPC cell therapy programmes to Fosun Pharma for Chinese market

    ReNeuron to receive upfront, near term and estimated success-based milestone payments of £80.0 million (US$104.8 million) and double-digit royalties on salesM

    https://finance.yahoo.com/news/reneuron-partners-fosun-pharma-china-110000716.html

    Good luck and GOD bless
    LONDON, April 9, 2019 /PRNewswire/ -- ReNeuron Group plc (RENE.L), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it has signed an exclusive licence agreement ("the Agreement") with Shanghai Fosun
    LONDON, April 9, 2019 /PRNewswire/ -- ReNeuron Group plc (RENE.L), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it has signed an exclusive licence agreement ("the Agreement") with Shanghai Fosun
    finance.yahoo.com
  • g
    georgejjl
    Further read-outs from the patients treated in the Phase 1/2 study will be presented at the 6th Annual Retinal Cell and Gene Therapy Innovation Summit, taking place in Vancouver, Canada, on 26 April 2019. Information regarding this conference may be found at: https://www.regonline.com/builder/site/default.aspx?EventID=2548135
    The Company will make a further announcement later this month, when these further read-outs from the study are known.
    The Company’s RP clinical programme benefits from Orphan Drug Designation in both Europe and the US, as well as Fast Track designation from the FDA.